Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026
Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Fineline Cube Jul 23, 2026
Company Medical Device

Vazyme Biotech Secures NMPA Nod for Two RSV Antigen Detection Kits

Fineline Cube Aug 8, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), a biotechnology company based in China, has announced that...

Company Deals

Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer

Fineline Cube Aug 8, 2024

Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S....

Company Drug

Servier’s Voranigo Receives FDA Nod for IDH Inhibitor as Brain Tumor Treatment

Fineline Cube Aug 8, 2024

The U.S. Food and Drug Administration (FDA) has granted first-time approval for Voranigo (vorasidenib), a...

Company

Organon’s Q2 2024 Revenues Grow 2% YOY, Sets Sights on Fertility Business Rebound in 2025

Fineline Cube Aug 8, 2024

Organon (NYSE: OGN), a U.S.-based pharmaceutical company, has reported its financial results for the second...

Company Drug

Akeso Biopharma Initiates Phase III Clinical Trial for Cadonilimab in Hepatocellular Carcinoma

Fineline Cube Aug 7, 2024

Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has announced the first patient...

Policy / Regulatory

China’s NMPA Proposes New Rules for Export Drug Manufacturing and Management

Fineline Cube Aug 7, 2024

The National Medical Products Administration (NMPA) of China has issued a new set of regulations...

Company Deals

JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies

Fineline Cube Aug 7, 2024

Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership...

Company Deals

Sangamo Therapeutics and Genentech Join Forces to Develop Genomic Therapies for Neurodegenerative Diseases

Fineline Cube Aug 7, 2024

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company based in the U.S., has entered...

Company

Merck KGaA Posts 1.7% Q2 Growth Amid Varied Business Segment Performance

Fineline Cube Aug 7, 2024

Merck KGaA (FRA: MRK) has reported its financial results for the second quarter of 2024,...

Company

Zai Lab’s Q2 2024 Revenues Soar 47% YOY, Driven by Vyvgart and Zejula Sales

Fineline Cube Aug 7, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has...

Company Deals

Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia

Fineline Cube Aug 7, 2024

Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese...

Company Deals

CybernaX Secures Licensing Deal with Merck KGaA for Advanced Lipid Storage Technology

Fineline Cube Aug 7, 2024

CybernaX, a biotechnology company based in Nanjing, has entered into a comprehensive licensing agreement with...

Company Deals

Shanghai Vitalgen BioPharma Partners with Novoprotein to Commercialize AaCas12bMax Gene Editor

Fineline Cube Aug 7, 2024

Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China,...

Company Drug

Walvax Biotechnology’s HPV Vaccine Price Cut Sparks Potential Market Price War in China

Fineline Cube Aug 7, 2024

Walvax Biotechnology Co., Ltd (SHE: 300142) has significantly reduced the price of its bivalent human...

Company Deals

Mabwell Bioscience Partners with Cristália for Biosimilar Denosumab in Brazil

Fineline Cube Aug 7, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered...

Company Deals

Daiichi Sankyo and MSD Broaden Partnership to Co-Develop T-Cell Engager MK-6079

Fineline Cube Aug 7, 2024

Daiichi Sankyo (TYO: 4568), a Japanese pharmaceutical company, has announced an expansion of its strategic...

Company

Bayer AG’s Q2 2024 Global Group Sales Rise 3.1%, Driven by Pharmaceuticals and Consumer Healthcare

Fineline Cube Aug 7, 2024

Bayer AG (OTCMKTS: BAYZF), a multinational pharmaceutical and life sciences company headquartered in Germany, has...

Company Drug

Antengene’s Xpovio Receives NDA Approval in Malaysia for Multiple Myeloma Treatment

Fineline Cube Aug 6, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced the approval...

Company Medical Device

Israeli Hair Transplant Innovator Hairstetics Launches First Procedure in Asia at Hainan Hospital

Fineline Cube Aug 6, 2024

Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone...

Company Drug

Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction

Fineline Cube Aug 6, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Posts pagination

1 … 350 351 352 … 699

Recent updates

  • MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
  • CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer
  • PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments
  • Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
  • OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.